Kyle Flannery1, Marley Boyd2, Jenny Black-Shinn2, Nicholas Robert2, Ashish M Kamat3. 1. Merck & Co., Inc., Kenilworth, NJ 07033, USA. 2. The US Oncology Network/McKesson Specialty Health, The Woodlands, TX 77380, USA. 3. Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
Authors: Matthew D Galsky; Amir Mortazavi; Matthew I Milowsky; Saby George; Sumati Gupta; Mark T Fleming; Long H Dang; Daniel M Geynisman; Radhika Walling; Robert S Alter; Mohamad Kassar; Jue Wang; Shilpa Gupta; Nancy Davis; Joel Picus; George Philips; David I Quinn; G Kenneth Haines; Noah M Hahn; Qianqian Zhao; Menggang Yu; Sumanta K Pal Journal: J Clin Oncol Date: 2020-04-09 Impact factor: 44.544
Authors: Aránzazu González-Del-Alba; Antonio José Conde-Moreno; Ana M García Vicente; Pilar González-Peramato; Estefanía Linares-Espinós; Miguel Ángel Climent Journal: Cancers (Basel) Date: 2022-02-23 Impact factor: 6.639
Authors: Laura S Wood; Dawn Conway; Maria Lapuente; George Salvador; Sheila Fernandez Gomez; Andrea Carroll Bullock; Geeta Devgan; Kathleen D Burns Journal: J Infus Nurs Date: 2022 May-Jun 01